Start-Up Portfolio

הידעת? הדפדפן שהינך גולש ממנו אינו עדכני

הדפדפן שהינך גולש ממנו אינו עדכני ויתכן שהאתר אינו יעבוד בצורה טובה. הדפדפנים הנתמכים באתר הם:

לחץ על האיקונים למעבר לדף ההורדה של הדפדפן

סגירת חלונית אל תציג בשנית

בסגירת החלונית תועבר/י לאתר מותאם לדפדפן ויתכן כי חלק מהאתר לא יעבוד בצורה מיטבית

Start-Up Portfolio

הדפסה דוא

 qrons-logo

 Fund Raising - Executive Summary

About Qrons

Founded in late 2016, Qrons is a publicly traded preclinical biotechnology company, developing advanced cell-based solutions to combat neurological injuries. While laser-focused on traumatic brain injury (TBI), the technology could potentially treat a wide range of neurodegenerative diseases.

About Traumatic Brain Injury.

Traumatic brain injuries (TBIs) are a severe form of neuronal damage caused by powerful head impacts. Patients can experience transient symptoms, profound disability or death. TBI is generally caused by violent acts, motor vehicle accidents, falls and sports-related concussions.

What TBI Does to the Brain.

Neuronal cells interconnect to create the gigantic network that drives core brain functions. Unfortunately, neurons rarely regenerate after an injury. As a result, following a severe brain injury, neural connectivity is lost and brain function compromised.

TBI patients can become blind, deaf, paralyzed and experience cognitive and psychological issues. There is also evidence that TBI patients are more likely to develop Alzheimer’s, Huntington’s, Parkinson’s and other neurodegenerative diseases. 

An Unmet Medical Need

TBI is the number one cause of death among young adults. In the U.S., there are more than two million brain injuries each year, and approximately 50,000 people die from these injuries. The direct and indirect medical costs exceed $76 billion annually.

There are no effective treatments to help patients regain function. Current treatments focus on reducing secondary injuries. They can partially reduce further damage but do little or nothing to heal the brain. Most strategies are rehabilitative helping patients adjust to their impaired cognitive state. 

Qrons was co-founded by individuals with extensive business experience and a history of delivering products and results. To overcome the complex challenges of TBI, Qrons is making use of rapidly changing advances in chemistry and molecular biology.  Qrons has developed a coordinated group of product-oriented research teams. Each team leverages different skill sets to tackle different challenges. This multidisciplinary approach is designed to produce a revolutionary TBI treatment.

The TBI treatment integrates proprietary, engineered mesenchymal stem cells (MSCs), 3D printable scaffolding, smart materials and a novel delivery system. Qrons believes this combination will reduce neuronal loss and functional impairment and possibly regenerate brain tissue and function for TBI patients.

Progress:

In less than 1 year of operation Qrons has achieved the following: 

Corporate:

 Became a Public Reporting Company by filing an S-1 Registration Statement which was declared effective by the SEC in May 2017. 

 Approved for Quotation by FINRA under the trading symbol QRON.

 Attained DTC Eligibility.

Scientific:

 Entered into License and Research Agreement with Ariel University.

 Conducting a Joint Study and entered into an Option License Agreement with Dartmouth College for the development of 3D printable advanced smart material. 

 Established and using innovative science protocols at Qrons research in Ariel for the development of genetically modified stem cells. Candidate genes modifications have been identified.

 Designed a revolutionary Research Plan that is ready to be implemented as part of this fund raise.

 Formation and growth of Science Advisory Board.

Fund raising

Qrons had initially conducted a friends and family funding raise to finance its setup, License Agreement with Ariel, public registration and first year of its operation. 

Qrons is now seeking funds to build on and advance its growth as it enters its second year of operations. Co-founders will continue to be compensated by equity only, and will not draw any salaries from this raise.

Use of funds:   To finance its R&D plan for 2018-2019, which consists of three separate research     groups, IP protection and patent prosecution and corporate operations and      professional fees. We expect another fund raise during the latter part of 2019.

Total funds sought:  $1.5 million.

Valuation:   To be mutually agreed upon.

Minimum investment: $250,000.

Company Capital Structure:  Common shares: 12 million common shares outstanding, of which with 2 million       shares are held by non-founders.  

     Preferred shares: Founders control voting through preferred shares. 

     Options plan: 0.4 million options.

Founders

Jonah Meer, Co-founder, Chief Executive Officer, Chief Financial Officer 

Jonah Meer is an attorney, accountant and entrepreneur who have worked for decades in the financial services and investment industries. Since 1998, he has been CEO of jTrade Global LLC. Meer leverages his extensive financial expertise and lifelong passion for business to lead Qrons’ growth.

Ido Merfeld, Co-founder and head of product

Ido Co-founded Ivory software systems and acted as its CEO for 25 years. Ido have an extensive experience in large software development projects and product team’s management. He began a second career in the molecular biology department at Ariel University. Ido will personally manage the product arm of Qrons. 

Our Partnership with Ariel University and Dartmouth College.

The Qrons team collaborates closely with Ariel University to develop and commercialize our products. Qrons has an exclusive license agreement with Ariel University to commercialize these technologies.

Qrons is collaborating with the Department of Chemistry at Dartmouth College. Together, we are developing innovative 3D printable, biocompatible advanced materials and stem cell delivery techniques. Qrons has an exclusive Option agreement with Dartmouth College to commercialize these technologies.

Contacts:

Jonah Meer, jmeer@qrons.com,  786 620 2140,  Ido Merfeld,  imerfeld @qrons.com +972 544576889, or visit our website at www.qrons.com.  

 

 

innoging logo

INNOGING MISSION IS TO ENABLE VIEWING AND ANALYZING REMOTELY RECORDED ULTRASOUND SCANS LIKE BEING NEXT TO THE PATIENT

BACKGROUND

Ultrasound is a dynamic real-time examination and very much operator dependent. Ultrasound was originally developed to be used by radiologists, but nowadays majority of ultrasound scans are done by technicians and only then reviewed by radiologists. This does not allow the radiologist to view and analyze the recorded exam in real-time, as originally intended. The radiologist totally relies on the technician scan, which may lead to insufficient diagnosis. iNNOGING's technology will allow the radiologists to view and analyze the recorded ultrasound scans as if taken by themselves and to improve diagnosis.

THE NEED

Following an ultrasound scan by the technician, the doctor needs to provide his diagnosis, but is limited in:

$1•      Viewing the recorded exam (he can only see images or video clips).

$1•      Navigating within the ultrasound exam.

$1•      Time to analyze each exam.

Therefore, doctors must rely on the technicians' skills and data quality. It becomes crucial when the recorded exam doesn’t contain sufficient information to complete the diagnosis. This might lead to errors, or inviting the patient to be re-scanned (this time by a doctor), or sending the patient to an unsafe and expensive exams (CT or MRI). iNNOGING's mission is provide the doctor an easy and fast tool to view remotely an ultrasound exam, as if he was next to the patient.

In addition to ultrasound diagnosis, ultrasound is best learned on real patients. Various companies developed costly ultrasound simulators for in university usage only. Thus, technicians, medicine students and doctors cannot practice at home, like with any other medical text book. iNNOGING developed a simulator that will allow to simulate real patient ultrasound diagnostics from anywhere.

THE MARKET

Ultrasound is a very common imaging tool, it is fast, safe, convenient and relatively not expensive. Therefore the market is growing rapidly.

ultrasound analysis

   

market value

$1.2B

 

u.s.a potential

106M SCANS

 

(out of 125M)

 
   
 

$30M

 

CAGR 15.2%  market value


ADI BARUCH, CEO

adi@innoging.com www.innoging.com +972-54-541-6000

COMPANY STATUS

Founded by Ariel university in 2015

Incorporate to iNNOGING in Q3/2017

STAGE

Alfa prototype has been developed and tested

INTELLECTUAL PROPERTY

Patent Pending (PCT): USA and Europe

KEY PERSONNEL

Adi Baruch, CEO

17 years of experience in the health care business in which 12 years of specialization as executive management in the international market including corporates and startups companies.

Yehiel Polatov, EVP and B.D.Ex-8200 commander, with 17 years of experience in the international arena including 8 years in the Ultrasound Simulation market, as VP BD, and in other senior positions in the video processing industry.

Dr. Nir Shwalb

INVENTOR & CTO Ph.D. in Robotics and Mechanical Engineering. Doctoral Thesis: Configuration Spaces For Parallel Mechanisms. Co-Head the Kinematics and Computational Geometry

Lab in Ariel University. Holds BSc in Mathematics, wrote


THE PRODUCT


simulator


31 scientific article as well as registered 9 patents.


ONE TECHNOLOGY – TWO PRODUCTS – ONE FOCUS

iNNOGING has developed an affordable device to be used with a standard computer from anywhere.

The solution allows the doctor to view and analyze the recorded ultrasound exams like being next to the patient and for students to practice

ultrasound scenarios.

iNNOGING's solution includes designated transducer/probe, touch pad and SaaS based software.

 

View our demo here:

Link1 and Link2

 

FUNDING

iNNOGING seeks seed funding of $1M for completing the simulator product and creating the foundation for the medical ultrasound diagnostic analyzer.


Eliad Moshe, VP R&D,

8 years of combined experience in software, hardware and robotics development in the medical, pharma and military spaces.

ADVISORY BOARD

Prof. Ada Kessler,

Head of Advisory Board and Chief Medical Advisor. Director of the Ultrasound division, Radiology Department, Ichilov-Souraski Medical Center, Tel Aviv, Israel. Active memberships: Israeli Radiological Association.

Israeli Society of Ultrasound in medicine.

EFSUM - European Federation of Societies for Ultrasound in medicine and Biology

SRU - American Society of Radiologist in Ultrasound

 

 diabest logo

Fund Raising - Executive Summary

About Diabest

Founded in 2011, Diabest is a privately held company, developing a botanical drug to treat diabetes, based on Sarcopoterium Spinosum extract. While sharply focused on type 2 diabetes and fatty liver disease, the technology could potentially treat a wide range of metabolic disorders.

 

About Diabetes

Diabetes is a number of diseases that involve problems with the hormone insulin. Normally, insulin helps our body store and use the sugar and fat from the food you eat. Diabetes can occur when the pancreas produces very little or no insulin (type 1 diabetes), or when the body does not respond appropriately to insulin (type 2 diabetes). Importantly, the most significant causes to type 2 diabetes are genetics and lifestyle (lack of exercise and overweight).

What Diabetes Does to the Body.

When the insulin cannot be used effectively, blood glucose levels rise while the rest of the body cells are deprived of much-needed energy. In addition, diabetes can cause long-term damage to our body. The long-term damage is commonly referred to as diabetic complications and it includes kidney damage, heart diseases, blindness, slow skin healing and stroke.

An Unmet Medical Need

It has been estimated that the world prevalence of diabetes will increase by 54% by 2030 to ~650 million patients. Although incidence rates of type 1 diabetes have remained fairly stable, the number of people diagnosed with type 2 diabetes has been steadily growing. Type 2 diabetes currently comprises ~90% of all diabetes cases in both the United States and Europe, and close to 100% in Asia. In 2015, an estimated 1.6 million deaths were directly caused by diabetes and another 2.2 million deaths were attributable to high blood glucose in 2012. The direct and indirect medical costs exceed $245 billion annually. As there is no cure for type 2 diabetes, patients are recommended to ‘manage blood glucose levels’ by diet, exercise. However, compliance with such regimens tends to be low and thus patients will eventually be prescribed medications. These medications, who act via various mechanisms, include insulin secretagogues, insulin sensitizers, α-glucosidase inhibitors, amylin analogs, incretin mimetics, insulin and SGLT2 inhibitors. However, although the number of approved medications is growing, the goal of treatment, which is maintaining an HbA1C of ≤ 7%, is still difficult to achieve, as around 50% of the patients do not responding suitably to the medications and fail to meet the desired glycemic goal., which fuels the demand for effective therapies.    

Diabest was co-founded by individuals with a history of delivering products and results. To overcome the complex challenges of diabetes, Diabest is making use of a S. spinosum, a traditional medicinal herb, used by Bedouin healers.  Diabest has developed a coordinated group of product-oriented research teams. Each team leverages different skill sets to tackle different challenges. This multidisciplinary approach is designed to produce a new diabetes treatment. The diabetes treatment integrates proprietary, S. spinosum growing and extraction. Diabest believes that S. spinosum will help to maintain healthy blood sugar levels and to evade diabetic complications.

Progress:

 

Corporate:

$11.      2011 Entered into License and Research Agreement with Ariel University.

$12.      2015 and 2016 Israel Innovation Authority funding (2,536,807 NIS)

$13.      National phase patent WO 2010143140 A3 and Provisional

 

 

Scientific:

$11.     S. spinosum root extract was found to exert a significant anti-diabetic effect in mice

$12.     Identified mechanism of action of S. spinosum extract, which is different from metformin

$13.     Data of diabetic mice treated with the extract showed improved glucose tolerance and reduced plasma insulin level (improves insulin sensitivity or mimic its effect in target tissues).

$14.     S. spinosum improved hepatic insulin sensitivity and reduced vacuoles of liver fat (hepatic steatosis) in type 2 diabetic mice and mice fed on high-fat diet

$15.     No visible toxicity

$16.     Plant harvesting, production of dry extract and capsulation

$17.     Optimization of S. spinosum growing protocol

$18.     Characterizing S. spinosum ecotypes generating increased biological activity

Fund raising

Diabest had initially conducted a friends and family funding raise to finance its setup License Agreement with Ariel and R&D. Diabest is now seeking funds to build on and advance its growth. Co-founders will continue to be compensated by equity only, and will not draw any salaries from this raise.

 

Use of funds:                           To finance its R&D plan for 2018-2019, which includes of human efficacy trails, IP                  protection and patent prosecution and corporate operations and professional fees.

Total funds sought:                 $1 million.

Valuation:                               To be mutually agreed upon.

Minimum investment:                         $100,000.

 

 

Team

Yitshak “Itsik” Francis

Dr. Yitshak Francis is director of business development at Ariel Scientific Innovations, Ariel University’s technology transfer company. Dr. Francis received his biology degree from the Technion in Israel and his Ph.D. in medical molecular biology from University College, London. He conducted his postdoctoral training at Columbia University, where he worked on several drug development projects. He was a co-founder and CEO for Citta Pharmaceuticals, a Columbia biotechnology spin-off that develops Alzheimer’s therapies.

 

Tovit Rosenzwieg, Co-founder and head of product

Dr. Tovit Rosenzwieg is a Head of Laboratory for Metabolism Research in Ariel University Center. The main research focus Dr. Rosenzweig is on the effects of adipokines on the physiologic function of pancreatic beta cells, effects of redox potential regulation on the development of diabetes, and studying the efficiency of local herbs as an anti-diabetic agents. 

 

Our Partnership with Ariel University.

The Diabest team collaborates closely with Ariel University to develop and commercialize our products. Diabest has an exclusive license agreement with Ariel University to commercialize these technologies.

Contacts:

Itsik Francis yitshakf@ariel.ac.il and Mobile: +972-54-877-1119. Web: https://diabestltd.wixsite.com/diabest

 

etv logo

 Creating the next generation of advanced Lithium Ion Batteries for electric vehicles, hybrids and high-end markets

 

ETV Energy is engaged in developing the next generation Lithium-Ion Battery (LIB) for the Automotive and High-end markets.

Novel battery chemistry based on a high voltage cathode is being developed for the automotive market to deliver specific energy of 220-250Wh/kg. The company has already gained a foothold in the high end market with a derivative of this technology that delivers 400Wh/kg. 

Read More

עדכון אחרון ב-שישי, 16 פברואר 2018 18:26
 

 

ברוכים הבאים לאתר אוניברסיטת אריאל בשומרון לכל צורכי הנגישות יש ללחוץ על כפתור הנגישות למעלה